Annamaria Ruzzo
TitleCited byYear
KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer
F Loupakis, A Ruzzo, C Cremolini, B Vincenzi, L Salvatore, D Santini, ...
British journal of cancer 101 (4), 715, 2009
PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer
F Loupakis, L Pollina, I Stasi, A Ruzzo, M Scartozzi, D Santini, G Masi, ...
Journal of clinical oncology 27 (16), 2622-2629, 2009
Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFOX-4 chemotherapy
A Ruzzo, F Graziano, F Loupakis, E Rulli, E Canestrari, D Santini, ...
Journal of clinical oncology 25 (10), 1247-1254, 2007
High concordance of KRAS status between primary colorectal tumors and related metastatic sites: implications for clinical practice
D Santini, F Loupakis, B Vincenzi, I Floriani, I Stasi, E Canestrari, E Rulli, ...
The oncologist 13 (12), 1270-1275, 2008
Pharmacogenetic profiling and clinical outcome of patients with advanced gastric cancer treated with palliative chemotherapy
A Ruzzo, F Graziano, K Kawakami, G Watanabe, D Santini, V Catalano, ...
J Clin Oncol 24 (12), 1883-1891, 2006
Intratumoural FOXP3-positive regulatory T cells are associated with adverse prognosis in radically resected gastric cancer
G Perrone, PA Ruffini, V Catalano, C Spino, D Santini, P Muretto, C Spoto, ...
European journal of cancer 44 (13), 1875-1882, 2008
Genetic activation of the MET pathway and prognosis of patients with high-risk, radically resected gastric cancer
F Graziano, N Galluccio, P Lorenzini, A Ruzzo, E Canestrari, S D'Emidio, ...
J Clin Oncol 29 (36), 4789-4795, 2011
Pharmacogenetic profiling for cetuximab plus irinotecan therapy in patients with refractory advanced colorectal cancer
F Graziano, A Ruzzo, F Loupakis, E Canestrari, D Santini, V Catalano, ...
Journal of Clinical Oncology 26 (9), 1427-1434, 2008
Prognostic analysis of E-cadherin gene promoter hypermethylation in patients with surgically resected, node-positive, diffuse gastric cancer
F Graziano, F Arduini, A Ruzzo, I Bearzi, B Humar, H More, R Silva, ...
Clinical Cancer Research 10 (8), 2784-2789, 2004
Genetic modulation of the Let-7 microRNA binding to KRAS 3′-untranslated region and survival of metastatic colorectal cancer patients treated with salvage …
F Graziano, E Canestrari, F Loupakis, A Ruzzo, N Galluccio, D Santini, ...
The pharmacogenomics journal 10 (5), 458, 2010
Toll‐like receptor 4 Asp299Gly and Thr399Ile polymorphisms in gastric cancer of intestinal and diffuse histotypes
D Santini, S Angeletti, A Ruzzo, G Dicuonzo, S Galluzzo, B Vincenzi, ...
Clinical & Experimental Immunology 154 (3), 360-364, 2008
Association of CDH1 haplotypes with susceptibility to sporadic diffuse gastric cancer
B Humar, F Graziano, S Cascinu, V Catalano, AM Ruzzo, M Magnani, ...
Oncogene 21 (53), 8192, 2002
Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFIRI chemotherapy
A Ruzzo, F Graziano, F Loupakis, D Santini, V Catalano, R Bisonni, ...
The pharmacogenomics journal 8 (4), 278, 2008
Interleukin 1B gene (IL-1B) and interleukin 1 receptor antagonist gene (IL-1RN) polymorphisms in Helicobacter pylori-negative gastric cancer of intestinal and …
A Ruzzo, F Graziano, F Pizzagalli, D Santini, V Battistelli, S Panunzi, ...
Annals of Oncology 16 (6), 887-892, 2005
Prognostic role of thymidylate synthase polymorphisms in gastric cancer patients treated with surgery and adjuvant chemotherapy
K Kawakami, F Graziano, G Watanabe, A Ruzzo, D Santini, V Catalano, ...
Clinical cancer research 11 (10), 3778-3783, 2005
Methylenetetrahydrofolate reductase 677C/T gene polymorphism, gastric cancer susceptibility and genomic DNA hypomethylation in an at‐risk Italian population
F Graziano, K Kawakami, A Ruzzo, G Watanabe, D Santini, F Pizzagalli, ...
International journal of cancer 118 (3), 628-632, 2006
Identification of seven novel germline mutations in the human E‐cadherin (CDH1) Gene
H More, B Humar, W Weber, R Ward, A Christian, C Lintott, F Graziano, ...
Human mutation 28 (2), 203-203, 2007
Combined analysis of E-cadherin gene (CDH1) promoter hypermethylation and E-cadherin protein expression in patients with gastric cancer: implications for …
F Graziano, F Arduini, A Ruzzo, A Mandolesi, I Bearzi, R Silva, P Muretto, ...
Annals of oncology 15 (3), 489-492, 2004
High let-7a microRNA levels in KRAS-mutated colorectal carcinomas may rescue anti-EGFR therapy effects in patients with chemotherapy-refractory metastatic disease
A Ruzzo, F Graziano, B Vincenzi, E Canestrari, G Perrone, N Galluccio, ...
The oncologist 17 (6), 823-829, 2012
Polymorphisms in genes involved in DNA repair and metabolism of xenobiotics in individual susceptibility to sporadic diffuse gastric cancer
A Ruzzo, E Canestrari, P Maltese, F Pizzagalli, F Graziano, D Santini, ...
Clinical Chemical Laboratory Medicine 45 (7), 822-828, 2007
The system can't perform the operation now. Try again later.
Articles 1–20